Drugs / Succimer
Succimer
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | CHEMET | — | 1991-01-30 | fda.gov ↗ |
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03957720 | Mar 2019 → Dec 2024 | Wilson disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03630991 | Oct 2018 → Apr 2027 expected | acute myeloid leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06811233 | May 2025 → Aug 2029 expected | acute myeloid leukemia | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00342849 | Jul 1994 → Aug 2007 | lead poisoning | National Institute of Environmental Health Sciences (NIEHS) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00004838 | Sep 1997 → Jul 1998 | lead poisoning | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00811083 Comparator | May 2005 → Apr 2007 | autism | Southwest College of Naturopathic Medicine | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | succimer | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004838 ↗ |
| Known as | 2,3-meso-dimercaptosuccinic acid | “Succimer (2,3-meso-dimercaptosuccinic acid) is an orally active dithiol compound that is a relatively specific chelating agent for heavy metals, especially lead.” NCT00342849 ↗ |
| Known as | dimercaptosuccinic acid | “receiving succimer (dimercaptosuccinic acid; DMSA) plus standard treatment” NCT00004838 ↗ |
| Known as | DMSA | “receiving succimer (dimercaptosuccinic acid; DMSA) plus standard treatment” NCT00004838 ↗ |
| Modality | Small molecule | “an orally active dithiol compound” NCT00342849 ↗ |
| Route | Oral | “Succimer is administered orally” NCT00004838 ↗ |